Axsome Therapeutics Provides Update on the New Drug Application for AXS-05 for the Treatment of Major Depressive DisorderGlobeNewsWire • 08/23/21
ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/16/21
ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/13/21
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/12/21
CORRECTING and REPLACING Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)Business Wire • 08/11/21
INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/11/21
Scott+Scott Attorneys at Law LLP Announces Investigation into Axsome Therapeutics Inc. (AXSM)Business Wire • 08/10/21
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors with Losses to Contact the FirmNewsfile Corp • 08/10/21
INVESTIGATION ALERT: The Schall Law Firm Announces It Is Investigating Claims Against Axsome Therapeutics, Inc. and Encourages Investors With Losses to Contact the FirmBusiness Wire • 08/09/21
AXSM INVESTOR ALERT: Rosen Law Firm Encourages Axsome Therapeutics, Inc. Investors with Losses to Inquire About Class Action Investigation – AXSMBusiness Wire • 08/09/21
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/09/21